Peter Hunt

Peter trained as a synthetic organic chemist, gaining a degree and PhD at Imperial College, University of London. He moved into the computational chemistry field during a postdoc at the 3D Centre in Australia, focussing on peptidomimetic design to address HIV protease inhibition and mimicry of bioactive peptides such as the Conotoxins. He returned to the UK in 1994 to join the CADD group of Merck & Co Inc and then moved to Novartis 2006. Prior to joining Optibrium in 2014, Peter lead the UK CADD group efforts in drug discovery and development research in the Neuroscience, Respiratory and Gastrointestinal disease areas. He is an inventor on over 20 patents, as well as a former chair of the TRIPOS User group and currently Secretary of the UK-QSAR committee.